Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

155.80 +8.57 (+5.82%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
20 21 Next >
News headline image
Choroidal Neovascularization Market Share Size Trends Overview Analysis 2022-2029
Global Choroidal Neovascularization Market to Witness Huge Growth by Key Players: Bausch Health Companies Inc, Bayer AG, Gilead Sciences Inc, F.Hoffmann –La Roche AG,MaaT Pharma Novartis AG, Pfizer... 
Via SBWire
News headline image
Cholecystitis Treatment Market Demand Trends Outlook Overview Analysis 2022-2029
Global Cholecystitis Treatment Market to Witness Huge Growth by Key Players: Boston Scientific, Dornier MedTech GmbH, Fresenius Kabi, AuroMedics Pharmaceuticals, Sanofi, SUNUET Pharmaceuticals, Hetero... 
Via SBWire
News headline image
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Europe Liver Cancer Therapeutics Market to Reach at High CAGR of 8.95% by 2023-2030
The Europe liver cancer therapeutics size was valued at US$ 384 million in 2022 and is estimated to reach US$ 627 million by 2030, growing at a CAGR of 8.95% during the forecast period (2023-2030) 
Via SBWire
News headline image
Mount Gilead, OH Author Publishes Children's Book
This Kids Book Features the Cutest Baby Elephant You Will Ever See! 
Via PR Leap
News headline image
Mount Gilead, NC Author Publishes Children's Book
So Excited, She Runs To Solve The Mystery Of What She Is Smelling. 
Via PR Leap
News headline image
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Europe Liver Cancer Therapeutics Market Is at the Cusp of Crossing CAGR of 8.95% N 2023-2030
Global Europe Liver Cancer Therapeutics Market to Witness Huge Growth by Key Players: Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead... 
Via SBWire
Topics Death
News headline image
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
News headline image
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Liposome Drug Delivery Market 2023 in-Depth Analysis, Growth, Size, Future Prospect, Regional Development and Global Outlook 2029
Liposome Drug Delivery Market Size, Share and Forecast 2023-2029 Key Players are – Ipsen Pharma, Celsion Corp, Gilead Sciences, Astellas Pharma, Johnson & Johnson, Luye Pharma Group, Novartis AG 
Via SBWire
News headline image
Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
From Gilead Sciences, Inc. and Arcellx, Inc.
Via Business Wire
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Mergers and Acquisitions in 2023 Off To A Strong Start
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road. 
Via MarketBeat
News headline image
Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Cell and Gene Therapy Market Size, Share, Industry Analysis, Growth Estimates, Trends, Demand and Forecast 2022-2028
Global Cell and Gene Therapy Market will worth USD 21,508 million by 2028-end at a CAGR of 28.2% from 2022 to 2028 according to Intelligence Market Report 
Via SBWire
News headline image
European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
From Arcus Biosciences
Via Business Wire
News headline image
Harpoon Therapeutics Remains Volatile After Promising News
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%. 
Via MarketBeat
News headline image
Gilead Sciences Again Named to Dow Jones Sustainability World Index
From Gilead Sciences, Inc.
Via Business Wire
News headline image
New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.